ATG is proposed to be an effective treatment in acquired PRCA (aPRCA) patients who do not respond to immune suppressive treatment.
However, this recommendation is based on old small case series, which represent a mixture of patients partly suffering other haematological disorders associated with aPRCA. To verify if ATG indeed provides an enduring response as >second line treatment in aPRCA, we want to retrospectively study the efficacy of ATG treatment in a large cohort of patients with aPRCA.
You are kindly invited to join this study and contribute your patient data. Patients are eligible if 1) they have been diagnosed with acquired PRCA and 2) received ATG treatment between 2000 and 2018.
Of note: patients who fulfil above criteria but have not received a transplant are eligible as well!
If you are interested to participate in this study, we would be very grateful if you could indicate your interest to Anne Lippinkhof (email@example.com) before May 1st 2021.
Stijn Halkes – Principal Investigator
Anne Lippinkhof – SAAWP Study Coordinator
Antonio Risitano – SAAWP Secretary
Régis Peffault de Latour – SAAWP Chair